Saturday 17 October 2026
Export JANX’s income statement to Excel — free account
Janux Therapeutics, Inc.
JANX Healthcare Biotechnology
Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024. In the quarter to June 2026, revenue grew 2,238.7%, EPS grew 36.4% and free cash flow grew 150.6%, each against the same quarter a year earlier.
16.49
0.83
−4.79%
Follow JANX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | — | 0.00 | 0.00 |
P/S ratio |
78.40 | — | 61.46 | 40.28 | |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | |
P/Operating CF |
(117.91) | — | (70.60) | 77.44 | |
P/B ratio |
1.55 | — | 0.93 | 1.04 | |
Price to Tangible BV |
1.55 | — | 0.93 | 1.04 | |
EV/Sales |
27.25 | — | (6.02) | (0.17) | |
EV/EBITDA |
0.00 | — | 0.50 | 0.03 | |
EV/Operating CF |
(7.48) | — | 1.10 | 0.10 | |
EV/FCF |
(7.38) | — | 1.09 | 0.10 | |
Quick Ratio |
35.54 | 38.67 | 16.83 | 16.14 | |
Current Ratio |
35.86 | 39.04 | 17.01 | 16.35 | |
Net Debt/EBITDA |
25.12 | 21.26 | 26.30 | 28.46 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.00 | 0.01 | 0.02 | |
Operating CF/Net income |
0.53 | 0.89 | 0.51 | (0.57) | |
Capex/Depreciation |
0.02 | 0.03 | 0.13 | 0.08 | |
Research and Development Expense of Revenue |
346.29% | 0.00% | 718.27% | 301.88% | |
Selling, General and Administrative Expense of Revenue |
106.22% | 0.00% | 298.23% | 106.78% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
90.44% | 0.00% | 248.30% | 88.26% | |
Graham Net Nets |
0.63 | — | 1.05 | 0.93 | |
Graham Number |
0.00 | — | 0.00 | 0.00 | |
Earnings Yield |
(6.87%) | — | (13.24%) | (10.68%) | |
Free Cash Flow Yield |
(4.71%) | — | (9.01%) | (4.34%) | |
Revenue per Share |
0.16 | 0.00 | 0.06 | 0.16 | |
Operating CF per Share |
(0.21) | (0.46) | (0.20) | 0.20 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.21) | (0.46) | (0.20) | 0.20 | |
Cash per Share |
15.95 | 15.60 | 15.26 | 15.43 | |
Shareholders Equity per Share |
15.74 | 15.44 | 15.02 | 14.74 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.74 | 15.44 | 15.02 | 14.74 | |
Free Cash Flow |
(12.95) | (28.65) | (12.61) | 12.28 | |
Working Capital |
970.26 | 950.89 | 943.13 | 923.19 | |
Capital Expenditures |
(0.09) | (0.11) | (0.27) | (0.20) | |
Net Current Asset Value |
949.88 | 931.14 | 915.36 | 903.67 | |
EV/EBIT |
0.00 | — | 0.54 | 0.03 | |
Capex to Sales |
0.01 | 0.00 | 0.07 | 0.02 | |
Price to Operating Income |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | — | 18.25 | 0.92 | |
Average Payables |
2.93 | 4.50 | 2.86 | 3.25 | |
Average Assets |
859.89 | 1,031.54 | 1,039.50 | 1,019.93 | |
Average Common Equity |
816.33 | 989.80 | 977.00 | 959.25 |
Columns are period end dates